Gliflozins that are used to inhibit SGLT2 and treat diabetes are very specific, but not totally specific for the SGLT2 transporter, they also act on other members of the SGLT family with lower affinity [24, 38]. This evidence concerns the gene SLC5A2 and diabetes mellitus.